Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care
暂无分享,去创建一个
Lisa P. Barrett | V. Martel-Laferrière | J. Montaner | M. Vachon | D. Rouleau | B. Conway | S. Walmsley | A. Rachlis | S. Sanche | Jim Young | M. Tyndall | N. Pick | C. Cooper | J. Cox | M. Klein | Lisa Jeff Brian Curtis Pierre Joseph John Shariq Mark M Barrett Cohen Conway Cooper Côté Cox Gill Ha | Jeff Cohen | P. Cote | S. Haider | M. Hull | R. Sandre | A. Wong | C. Rossi | M. Gill | E. Moodie | J. Gill | A. Sadr | Marina B Klein
[1] AASLD/IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C , 2018, Clinical Liver Disease.
[2] J. Losa,et al. All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings , 2018, Hepatology.
[3] N. Martin,et al. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it? , 2018, Journal of the International AIDS Society.
[4] S. Saab,et al. Hepatitis C and human immunodeficiency virus coinfection in the era of direct‐acting antiviral agents: No longer a difficult‐to‐treat population , 2018, Hepatology.
[5] C. Hézode. Treatment of hepatitis C: Results in real life , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[6] S. Pol,et al. Treatment of hepatitis C: the use of the new pangenotypic direct‐acting antivirals in “special populations” , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[7] C. Sutcliffe,et al. High hepatitis C cure rates among black and nonblack human immunodeficiency virus–infected adults in an urban center , 2017, Hepatology.
[8] Z. Butt,et al. A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia , 2017, PloS one.
[9] J. Rockstroh,et al. Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there? , 2017, Journal of the International AIDS Society.
[10] J. Rockstroh,et al. Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection , 2017, Open forum infectious diseases.
[11] D. Neau,et al. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. , 2017, Journal of hepatology.
[12] P. Belperio,et al. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1–Coinfected Patients Treated in Routine Practice , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] M. Manns,et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.
[14] K. Kowdley,et al. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection , 2017, Hepatology.
[15] D. Nelson,et al. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. , 2017, Annals of internal medicine.
[16] V. Martel-Laferrière,et al. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] O. Weiland,et al. The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease , 2017, BMC Infectious Diseases.
[18] P. Belperio,et al. Real-World Effectiveness and Predictors of Sustained Virological Response with All-Oral Therapy in 21,242 Hepatitis C Genotype-1 Patients , 2016, Antiviral therapy.
[19] F. Palella,et al. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. , 2016, The Journal of antimicrobial chemotherapy.
[20] J. Rockstroh,et al. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection , 2016, Current opinion in HIV and AIDS.
[21] J. Rockstroh,et al. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01). , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] D. Dieterich,et al. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] P. Easterbrook,et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.
[24] Sander Greenland,et al. Sparse data bias: a problem hiding in plain sight , 2016, British Medical Journal.
[25] V. Martel-Laferrière,et al. How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World? , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] M. Klein,et al. Epidemiology of hepatitis C virus in HIV-infected patients , 2015, Current opinion in HIV and AIDS.
[27] P. Harrigan,et al. Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. , 2015, Drug and alcohol dependence.
[28] K. Mounzer,et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. , 2014, JAMA.
[29] M. Buti,et al. Natural history and management of hepatitis C: does sex play a role? , 2014, The Journal of infectious diseases.
[30] P. Bruggmann,et al. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] G. Dore,et al. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. , 2013, The Journal of infectious diseases.
[32] C. Cooper,et al. Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] Hong Yang,et al. Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. , 2010, International journal of epidemiology.
[34] A. el-Zayadi,et al. Hepatitis C comorbidities affecting the course and response to therapy. , 2009, World journal of gastroenterology.
[35] Sander Greenland,et al. Prior data for non‐normal priors , 2007, Statistics in medicine.
[36] Sander Greenland,et al. Bayesian perspectives for epidemiological research. II. Regression analysis. , 2007, International journal of epidemiology.
[37] R. Gandhi. Cirrhosis is associated with low CD4+ T cell counts: implications for HIV-infected patients with liver disease. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] Sander Greenland,et al. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. , 2006, International journal of epidemiology.
[39] J. Montaner,et al. Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users , 2002, Hepatology.
[40] D. Kivlahan,et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. , 1998, Archives of internal medicine.
[41] F. Leri,et al. Heroin and cocaine co-use in a group of injection drug users in Montréal. , 2004, Journal of psychiatry & neuroscience : JPN.